In a phase 2 trial of 276 Chinese women with moderate-to-severe menopausal vasomotor symptoms, GS1-144 30 mg twice daily reduced frequency vs placebo at weeks 4 and 12, and 60 mg once daily at week 12. Adverse events: 67.6% vs 62.3% with placebo.
RCTn = 276
Wang et al. Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial